We confirmed the therapeutic efficacy of IL-32 in subcutaneously injected MC38 colon adenocarcinomas (Figure 4E) and orthotopically inoculated 4T1 mammary carcinomas (Figure 4F). This evidence concerns the gene IL32 and colon adenocarcinoma.